01.08.26 -- Trading Places: 2025 Intensified CDMOs Recruiting Sponsor Talent

Advances in peptide drug delivery have opened new opportunities for peptide drug products, with non-parenteral routes of administration — such as oral and nasal — now feasible.

Through close collaboration, proactive communication, and agile project management, our partnership accelerated an oncology program and helped overcome complex preclinical hurdles.

JHS partnered with a global pharma company to optimize biologic production, increasing output by 50% and reducing batch release times by up to 30%.

This analysis identifies key compliance trends and regional disparities by examining the 2025 U.S. FDA warning letters issued to drug product manufacturers posted between Jan. 1 and Dec. 9, 2025.

High-concentration protein formulations improve patient convenience but face challenges like surfactant degradation. Innovative strategies optimize stability and quality for development.

Recognizing what it takes to complete technology transfers effectively and efficiently is crucial to selecting the best partner for your project and product needs.

Process development bridges early discovery and clinical manufacturing, reducing risk, improving scalability, and aligning biologic programs with regulatory and commercial success from the start.

BD Vystra Disposable Pen is a proven, globally adopted drug delivery platform with over 175 million units sold, supporting diverse therapies in 40+ countries.

Transferring cell cultures between scales is challenging and error-prone. Discover a bioreactor scaling software that predicts optimal settings to enable efficient scale-up and progression to clinical studies.

Discover reliable, customized injectable fill/finish solutions. Expertise covers high-potent drugs, ADCs, and biologics, supported by two aseptic sites and global regulatory compliance.

The streamlined collaboration encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.

Leverage the expertise of three industry leaders collaborating seamlessly to take your ADC from DNA to aseptic fill faster than ever.